Biotechnology company · MDGL

Madrigal Pharmaceuticals
clinical trial
pipeline

Registry checked

Published

Resmetirom is linked to 8 distinct active studies, with 1 Phase 1, 2 Phase 2, 3 Phase 3, 1 Phase 4, 1 without a recorded phase.

Phase 3 study NCT05500222 in NASH and Cirrhosis, Liver lists estimated primary completion in December 2026. Phase 3 study NCT04951219 in Non-Alcoholic Fatty Liver Disease lists estimated primary completion in March 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

8active trials
as lead sponsor
  • Phase 11
  • Phase 22
  • Phase 33
  • Phase 41
  • Phase not recorded1

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

22 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 02

Select an example to see what changed

01Recruitment status
Not yet recruitingRecruiting

Resmetirom in Patients With MASH and HFpEF

NCT07830758 · ClinicalTrials.gov
Recorded by ComplyRx
16 Oct 2026
Registry last updated
16 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-162000022
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals2000022 distinct

02 / Drugs & programmes

Explore the pipeline

1 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Resmetirom

Canonical investigational asset

8
Active trials
5
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 22
  • Phase 33
  • Phase 41
  • Phase not recorded1
Studied condition
Cirrhosis, Liver · Heart Failure With Preserved Ejection Fraction (HFPEF) · MASH
Next primary completion
Dec 2026 · estimated
Open drug

8 of 8 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

1 selected programmes · accepted investigational links cover 8 of 8 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Madrigal Pharmaceuticals trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
5 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Resmetirom

NCT05500222

Phase 3 · Active, not recruiting

Trial source and qualifications

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

3 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 26 Aug 2022 · actual
    Primary completion: Dec 2026 · estimated
    Study completion: Jan 2027 · estimated

    2021202220232024202520262027202820292030
    A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
    Resmetirom

    NCT04951219

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

    4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    4 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 09 Jul 2021 · actual
      Primary completion: Mar 2027 · estimated
      Study completion: Apr 2027 · estimated

      2021202220232024202520262027202820292030
      MAESTRO-NASH
      Resmetirom

      NCT03900429

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

      Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      Start clipped at the display horizon.

      1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 28 Mar 2019 · actual
        Primary completion: Jan 2028 · estimated
        Study completion: Jan 2028 · estimated

        2021202220232024202520262027202820292030
        Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
        Resmetirom

        NCT07335601

        Phase 2 · Recruiting

        Trial source and qualifications

        Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

        3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        3 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 29 Dec 2025 · actual
          Primary completion: Aug 2028 · estimated
          Study completion: Mar 2029 · estimated

          2021202220232024202520262027202820292030
          Study of Resmetirom in Children and Adolescents With MASH
          Resmetirom

          NCT07763015

          Phase 2 · Recruiting

          Trial source and qualifications

          Study of Resmetirom in Children and Adolescents With MASH

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

          2 candidate observations · 2 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          Up to three verified eligible observations in the bounded history window.

          • new trial · Recorded 2026-08-14 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
          • status flip · Recorded 2026-09-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

          Start: 01 Aug 2026 · actual
          Primary completion: Jul 2029 · estimated
          Study completion: Jul 2029 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          5 selected of 5 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 0 actual primary completions, 0 untyped primary completions, 0 past estimates, 0 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          5

          active trials in Metabolic/Endocrine/Nutrition

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Metabolic/Endocrine/Nutrition5 trials
          • Gastroenterology & Hepatology3 trials
          • Unmapped0 trials
          • Healthy volunteers0 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies

          No supported overlap was identified in the selected programme context. Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Canonical current-owner attribution covers 46 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Madrigal Pharmaceuticals, Inc.. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          46 distinct registry candidates produced 46 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          46 scoped records have indexed enrichment and 0 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-11-01T02:29:40.242Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot c987902766f518720b758c88e4b708390a38d8d1b97aeeaea06d8dacaf68a1d2.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 46 mapped lead-sponsored clinical studies across all statuses. 46 have indexed enrichment. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.